REG - Abingdon Health PLC - Trading on the OTCQB Venture Market in the US

Abingdon HealthAnnouncement

10/03/2026 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260310:nRSJ9476Va&default-theme=true

RNS Number : 9476V  Abingdon Health PLC  10 March 2026

 

Abingdon Health plc

("Abingdon Health", the "Group" or the "Company")

 

Trading on the OTCQB Venture Market in the US

 

York, (UK) and Madison, WI (US) 10 March 2026: Abingdon Health plc (AIM: ABDX)
(OTCQB: ABDXF), a leading international developer, manufacturer and regulatory
services provider for rapid diagnostic tests and med-tech, announces that
trading in the Company's ordinary shares will begin next month on the OTCQB
Venture Market ("OTCQB") in the United States, under the ticker symbol
"ABDXF".

 

By trading on the OTCQB, Abingdon Health shares will be available to trade in
US dollars by investors during US working hours. Being available on the OTCQB
platform has the potential to increase liquidity in Abingdon Health shares on
AIM by attracting a larger universe of investors. The OTCQB is designed for
entrepreneurial and development stage US and international companies.

 

Abingdon Health announced the second phase of a facility expansion at its
Madison, Wisconsin (US) site in September 2025
(https://www.londonstockexchange.com/news-article/ABDX/us-cdmo-operations-update/17208008)
. Having raised the proceeds to support and expedite this growth in October
2025
(https://www.londonstockexchange.com/news-article/ABDX/result-of-placing-and-notice-of-gm/17277463)
, this build-out will complement Abingdon Health's UK operations to allow
manufacturing for customers under the same conditions and quality management
system in either the USA, the UK, or both. The US expansion will provide
customers with unrivalled geographic optionality during a period of tariff and
supply chain uncertainty, and provides US customers with the knowledge that
their products "developed in the USA" by the Company's highly skilled CDMO
team can also be "made in the USA".

 

Foreign Private Issuers, such as Abingdon Health, that trade on the OTCQB are
exempt under the US Exchange Act Rule 12g3-2(b) from SEC reporting if they
make whatever information is required by their home market regulator publicly
available to US investors in English. Abingdon Health will therefore face no
extra reporting obligations and incur minimal ongoing costs as a result of the
Company's Ordinary Shares being traded on the OTCQB.

 

Abingdon Health's Ordinary Shares will continue to trade on the London Stock
Exchange's AIM Market under the symbol "ABDX".

 

Chris Hand, Executive Chairman, commented: "Having seen our physical footprint
and customer portfolio grow in the US following the establishment and
expansion of our facility in Madison, Wisconsin, we believe that Abingdon
Health is becoming increasingly relevant to US investors. This OTCQB launch
will not only make our shares accessible to investors in the US - the largest
lateral flow and med-tech market in the world with significant areas of unmet
need - but also increase liquidity and benefit our investors on AIM. We look
forward to meeting and engaging with our new US investors soon."

 

Any shareholders wishing to keep up to date with Abingdon Health news, please
email abingdon@walbrookpr.com

 

Enquiries:

 Abingdon Health plc                           www.abingdonhealth.com/investors/ (http://www.abingdonhealth.com/investors/)
 Chris Hand, Executive Chairman                                          Via Walbrook PR

 Tom Hayes, CFO

 Cavendish Capital Markets Limited (Sole Broker and Nominated Adviser)                               Tel: +44 (0)20 7220 0500
 Geoff Nash / Isaac Hooper / Joe Smith (Corporate Finance)

 Nigel Birks (Life Science Specialist Sales)

 Walbrook PR (Media & Investor Relations)      Tel: +44 (0)20 7933 8780 or abingdon@walbrookpr.com
                                               (mailto:abingdon@walbrookpr.com)
 Paul McManus / Alice Woodings                 Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654

 

 

About Abingdon Health

 

Abingdon Health Group is a leading med-tech contract service provider
offering its services to an international customer base.

 

The Group's CDMO
(https://www.abingdonhealth.com/services/your-complete-lateral-flow-partner/)
(Contract Development and Manufacturing Organisation) expertise offers lateral
flow product development, regulatory support, technology transfer and
manufacturing services for customers looking to develop new assays or transfer
existing laboratory-based assays to a lateral flow format.  Abingdon Health
has the internal capabilities to take lateral flow projects, in areas such as
infectious disease and clinical testing, including companion diagnostics,
animal health and environmental testing, from initial concept through to
routine manufacturing; from idea to commercial success.

 

Abingdon's regulatory services companies, Compliance Solutions (Life Sciences)
and IVDeology, provide a broad range of regulatory services to the in vitro
diagnostic and wider medical device industry, to support customers in bringing
products to market across a range of territories including the USA, EU and the
UK.  Its consultancy services range from design, implementation and
maintenance of quality management systems, preparation of technical files for
regulatory approvals, part-time and interim management support, auditing both
internal and external, management reviews and presentations, training and
mentoring.   The Company's subsidiary, Abingdon Analytical Ltd, offers
analytical testing and performance evaluation to generate the required
technical and data for regulatory approval for lateral flow and other in vitro
diagnostic assays from its Doncaster, England facilities.

 

Founded in 2008, Abingdon Health is headquartered in York, England with
laboratories in Doncaster, England and laboratories and commercial offices in
Madison, Wisconsin, USA.

 

Abingdon Health's brochure
(https://www.abingdonhealth.com/wp-content/uploads/2025/06/Abingdon-Health-Group-Leaflet-JUN2025.pdf)
 outlines the comprehensive support the Group can now provide to its
international customers.  For more information visit: www.abingdonhealth.com
(https://urldefense.proofpoint.com/v2/url?u=http-3A__www.abingdonhealth.com_&d=DwMFAg&c=euGZstcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM&r=b40MoFA_Q_fdsT77LXB5t3JFUZjlmpd2MVbmgvoBIOo&m=5rmPWmSeAYNtvo-wVGL_4V7p0wZ2qRPhbqDj6E6FHnhVakMVyzvk7wZG1jS6vI4P&s=Cd1Yy0EoU5vx33xedoTE3bCKbljgDOIRD8ol-bb59BM&e=)
.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFLFEAVAIAIIR



            Copyright 2019 Regulatory News Service, all rights reserved